



Neuren (NEU) - ASX Announcement

30 April 2018

Neuren announces grant of first patent in Japan for trofinetide

Melbourne, Australia, 30 April 2018: Neuren Pharmaceuticals (ASX: NEU) today announced the grant of the first patent by the Japan Patent Office for trofinetide. The new patent titled “Treatment of autism spectrum disorders using glycyl-L-2-methylprolyl-L-glutamic acid” covers trofinetide treating patients with autism, Rett syndrome, and Fragile X syndrome. After issue, the patent will expire in January 2032, with the potential to be extended for up to 5 years.

Neuren Executive Chairman Richard Treagus commented: “The grant of this patent in Japan now enables Neuren to pursue the development and commercialization of trofinetide in one of the most important pharmaceutical markets in the world.”

Trofinetide is covered by issued composition of matter patents in the United States and in Europe, as well as issued patents in the United States, Europe and Australia concerning the use of trofinetide to treat Rett syndrome, Fragile X syndrome and other autism spectrum disorders. Applications are pending in Canada, Brazil and Israel.

About Neuren and trofinetide

Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company developing new therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Neuren has completed Phase 2 development of trofinetide for Rett syndrome and has completed a Phase 2 clinical trial in Fragile X syndrome. The programs for trofinetide in Rett syndrome and Fragile X syndrome have each been granted Fast Track designation by the US Food and Drug Administration and Orphan Drug designation in both the United States and the European Union. Trofinetide is a synthetic analogue of a naturally occurring neurotrophic peptide derived from IGF-1, a growth factor produced by brain cells. In animal models, trofinetide exhibits a wide range of important effects including inhibiting neuroinflammation, normalizing the role of microglia, correcting deficits in synaptic function and regulating oxidative stress response.

For more information, please contact:

Dr Richard Treagus, Executive Chairman: rtreagus@neurenpharma.com; +61 417 520 509

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.